Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Catalyst Pharmaceuticals (CPRX) EBIAT (2016 - 2025)

Historic EBIAT for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $52.8 million.

  • Catalyst Pharmaceuticals' EBIAT rose 2027.85% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.6 million, marking a year-over-year increase of 5235.89%. This contributed to the annual value of $163.9 million for FY2024, which is 12950.43% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported EBIAT of $52.8 million as of Q3 2025, which was up 2027.85% from $52.1 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' EBIAT registered a high of $56.7 million during Q1 2025, and its lowest value of -$30.8 million during Q3 2023.
  • For the 5-year period, Catalyst Pharmaceuticals' EBIAT averaged around $27.3 million, with its median value being $25.5 million (2022).
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' EBIAT plummeted by 23523.83% in 2023, and later skyrocketed by 24264.73% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' EBIAT (Quarter) stood at $9.3 million in 2021, then soared by 173.62% to $25.5 million in 2022, then soared by 36.8% to $34.8 million in 2023, then soared by 60.53% to $55.9 million in 2024, then dropped by 5.64% to $52.8 million in 2025.
  • Its last three reported values are $52.8 million in Q3 2025, $52.1 million for Q2 2025, and $56.7 million during Q1 2025.